Systagenix Wound Management (US), Inc.

Kci USA, Inc.

Ethicon, Gmbh

Systagenix Wound Management, Limited

Kci Licensing, Inc.

Woundchek Laboratories (US), Inc.

Woundcheck Laboratories (US), Inc.

Johnson & Johnson Medical Gmbh

Systagenix Wound Management IP Co B.v.

Sara Jayne Gregory

Breda Mary Cullen

Claire Boyle

Derek Walter Silcock

Deborah Addison

Derek Silcock

Rachael Louise Clark

Patrick John Trotter

David Greenhalgh

William Pigg

Alexander Waite

Paul W Watt

Paul Howard Lowing

Simon William Bayliff

Alicia Essler

Ryan Moseley

Philip Stephens

Faraia Shah

Margaret Stedman

Christopher Brian Locke

Timothy Mark Robinson

Michelle Delbono

Craig Delury

Michelle Del Bono

Sarah-Jayne Gregory

Jonathan Warrick

Lindsay Page

Rachael Louise McInnes

Lindsay Matheson

Clare Boyle

James Boyle

Alicia Esseler

A dressing configured to be positioned adjacent to a tissue site is disclosed herein. The dressing may include oxidized regenerated cellulose (ORC), collagen, and at least one nutrient including glutamine. Methods of treating a tissue site are also disclosed herein.

Nutrient-enriched dressing

A polyurethane foam wound dressing, the foam integrally comprising an oxidoreductase enzyme and a substrate for the enzyme. The foam is produced by mixing a polyurethane polymer, water, an oxidoreductase enzyme and substrate for the enzyme and drying the resulting product.

Composition

A wound dressing comprising: a water-absorbent fabric comprising at least about 10 wt. % of hydrogel-forming absorbent fibers based on the dry weight of the fabric; and an adhesion-resistant, water-permeable wound contacting surface textile layer that is substantially continuously bonded to at least one surface of said fabric. The surface textile layer may be formed by surface treatment of the fabric, or by bonding a suitable textile web to the surface of the fabric.

Hydrogel wound dressings exhibiting reduced fiber losses in use

A wound dressing material for controlled activation of a wound healing therapeutic compound in the presence of a protease enzyme in a wound fluid, the material comprising: a medically acceptable polymer; a wound healing therapeutic agent; an inhibitor of the protease enzyme; and a linker group which is cleavable by the protease enzyme wherein the activities of both the wound healing therapeutic agent and the inhibitor increased by contacting the wound dressing material with a would fluid containing the protease enzyme. For example, the enzyme may be a matrix metalloproteinase, the therapeutic agent may be a reactive oxygen scavenger, and the inhibitor may be a tissue inhibitor of metalloproteinase (TIMP).

Wound dressings for the controlled release of therapeutic agents

A wound dressing composition comprising a non-viable cell lysate or releasate derived from a hepatocyte cell or an inflammatory cell such as a macrophage. Also provided are wound dressings comprising such compositions, methods of making such compositions, and the use of such compositions for the treatment of wounds.

Wound dressing compositions

A wound dressing material may include a polymeric substrate, a silver salt, and a dyestuff to photostabilize the silver salt. The substrate may include collagen and/or oxidized regenerated cellulose complexed to Ag+, and the dyestuff may, for example, be an aniline or acridine dye. Also disclosed are methods of making such materials, and wound dressings that include such materials.

Antioxidant and antimicrobial wound dressing materials

Systems, methods, and apparatuses for modulating proteases including matrix metalloproteinase (MMP), elastase, and bacterial protease in a negative pressure therapy system are described. A mesh having a sacrificial substrate is included. The sacrificial substrate includes a plurality of collagen fibers reinforced with a supporting material and intersecting with each other to form a network of collagen fibers having a plurality openings. The openings of the plurality of openings have an average area between about 0.5 mmand about 20 mmto permit the flow of negative pressure through the mesh. The sacrificial substrate can also include oxidized regenerated cellulose.

Protease modulating wound interface layer for use with negative pressure wound therapy

A wound dressing material for controlled activation of a wound healing therapeutic compound in the presence of a protease enzyme in a wound fluid, the material comprising: a medically acceptable polymer; a wound healing therapeutic agent; an inhibitor of the protease enzyme; and a linker group which is cleavable by the protease enzyme, wherein the activities of both the wound healing therapeutic agent and the inhibitor are increased by contacting the wound dressing material with a would fluid containing the protease enzyme. For example, the enzyme may be a matrix metalloproteinase, the therapeutic agent may be a reactive oxygen scavenger, and the inhibitor may be a tissue inhibitor of metalloproteinase (TIMP).

A wound dressing composition comprising a chitosan and an oxidized cellulose. For example, the composition may be in the form of a sponge formed by freeze drying an aqueous dispersion of chitosan and oxidized regenerated cellulose (ORC). The composition is especially suitable for the treatment of chronic wounds.

Compositions for wound treatment

The present invention relates to monitoring patients for an inflammatory condition or infection (preferably wound infection) by testing an extracellular fluid such as a wound fluid for an elevated level of: (i) vimentin; (ii) a vimentin breakdown product; or (iii) a marker indicative of the presence of vimentin. The present invention provides methods of diagnosis and prognosis, wound dressings, devices (e.g. biosensors) and kits for use in such methods.

Measurement of cytoskeletal proteins and uses thereof in diagnosis, prognosis and therapy

A wound dressing material comprising a polymeric substrate, a silver salt, and a dyestuff to photostabilize the silver salt. The substrate may comprise collagen and/or oxidized regenerated cellulose complexed to Ag, and the dyestuff may for example be an aniline or acridine dye.

A wound dressing material for controlled activation of a wound healing therapeutic compound in the presence of a protease enzyme in a wound fluid, the material comprising: a medically acceptable polymer; a wound healing therapeutic agent; an inhibitor of the protease enzyme; and a linker group which is cleavable by the protease enzyme, wherein the activities of both the wound healing therapeutic agent and the inhibitor are increased by contacting the wound dressing material with a wound fluid containing the protease enzyme. For example, the enzyme may be a matrix metalloproteinase, the therapeutic agent may be a reactive oxygen scavenger, and the inhibitor may be a tissue inhibitor of metalloproteinase (TIMP).

Wound dressing for the controlled release of therapeutic agents

The present invention relates to the diagnosis, prognosis and/or treatment of wound infection by testing wound fluid for the presence of a marker which is present in an amount which is indicative of infection. The marker may be high molecular weight phospholipase A(cPLA) or a marker which is correlated with cPLA.

[object Object]

Growing community of inventors

Skipton, United Kingdom

Breda Mary Cullen